3D Systems Q1 2026 revenue $95.5M, turns profitable with medical 3D printing leading

3D Systems reported Q1 2026 revenue of $95.5 million, up 1% year-over-year, with adjusted EBITDA turning positive at $2.1 million — a $25.9 million improvement from the $23.9 million loss in Q1 2025. Excluding the 2025 divestiture of its Geomagic and 3DXpert software businesses, organic revenue grew 11%. Healthcare revenue hit $50.1 million, up 21% year-over-year, now matching industrial revenue for the first time. Dental grew over 20% driven by single-denture 3D printing systems, while orthopedic implants — including titanium hip cups and spinal cages — surpassed 3 million cumulative units. Industrial revenue declined 15% to $45.4 million, though aerospace and defense posted double-digit growth on metal LPBF parts for satellite structures and engine components.

This earnings report marks a structural turning point for 3D Systems, a company that spent years restructuring after the 2020–2022 SPAC-era hype cycle. The medical segment is now the primary growth engine, pulling the company to adjusted EBITDA profitability for the first time in years. This mirrors a broader industry pattern: medical and dental applications — where qualification pathways are clearer and per-part margins higher — are becoming the reliable revenue base for legacy AM OEMs, while industrial segments remain lumpy and tied to program-duration cycles. The 21% medical growth also validates that 3D Systems is capturing value in the dental digital workflow transition, a segment where Align Technology (via VPP) has long dominated but where LPBF and SLA-based production are expanding. The company's ability to sustain this trajectory depends on whether it can scale its metal DMP printer sales into aerospace programs without the margin erosion that has plagued other OEMs.

For investors and buyers, the practical takeaway is that 3D Systems has stabilized its core business around medical production, but the industrial side remains a work in progress. The company needs to demonstrate that its metal LPBF platforms — DMP Flex 200, DMP 350 Triple, and DMP 500 — can win repeat orders in aerospace and defense beyond the current program-specific wins. The full-year adjusted EBITDA breakeven target is achievable if medical growth holds and cost controls stick, but the Q2 guidance of $93–95 million revenue and slightly negative EBITDA suggests the recovery is still fragile. This is a company that has stopped bleeding but has not yet proven it can grow profitably at scale.